Fairvalue-Calculator Fairvalue-Calculator
EN DE

Chongqing Lummy Pharmaceutical Co (300006) Fair Value & Analysis

Healthcare · CN · Market cap 5.4B CNY

Price¥4.62
Fair Value¥1.13
Upside-75.5%
Quality94/100
Evidence: Medium Range ¥1.03 – ¥1.30

Fair value as of: Jun 24, 2026

Analysis

Chongqing Lummy Pharmaceutical Co (300006) currently trades at ¥4.62, while our model-based Fair Value estimate is ¥1.13 — implying the stock looks roughly 75.5% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. The company was founded in 1999 and is headquartered in Chongqing, China.

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -60% Johnson & Johnson, (JNJ) -47% AbbVie Inc (ABBV) -52% Roche Holding (ROGN) -20% Merck & Co (MRK) -45% AstraZeneca PLC (A1ZN34) -85%

Frequently asked questions

Is Chongqing Lummy Pharmaceutical Co (300006) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥1.13 versus a price of ¥4.62 — about −76% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 300006?
Our 21-model fair value for Chongqing Lummy Pharmaceutical Co is ¥1.13 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥4.62.
What is the quality score of 300006?
Chongqing Lummy Pharmaceutical Co has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.